Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose-intensity versus standard checkpoint inhibitor immunotherapy after 6 months of response in metastatic cancer
2021-000615-23Phase 3Active
- Sponsor
- Unicancer
- Start
- Jun 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, durvalumab, atezolizumab, avelumab, nivolumab and 3 more in non-small cell lung cancer (NSCLC), metastatic renal cell carcinoma (mRCC), head and neck cancer (HNC) and 5 more (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)metastatic renal cell carcinoma (mRCC)head and neck cancer (HNC)bladder cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2021-000615-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000615-23.